Stevens-Johnson Syndrome: A Legal Guide for Patients and Families

What Is Stevens-Johnson Syndrome?

A medication was prescribed to help you. You filled the prescription, trusted the process, and followed instructions. Then your body began to fall apart. What happened to you has a name: Stevens-Johnson Syndrome, and it is almost always caused by a drug that someone failed to prescribe, monitor, or warn about properly.

Stevens-Johnson Syndrome, or SJS, is a severe, life-threatening reaction to a medication that causes the skin and the mucous membranes lining the mouth, eyes, throat, and genitals to blister, ulcerate, and separate from the body. It is not an allergy in the ordinary sense. It is an immune system catastrophe, and it typically begins within one to three weeks after starting a new drug. The National Library of Medicine and the National Organization for Rare Disorders (NORD) both maintain detailed clinical overviews of SJS for patients and families.

The SJS/TEN Disease Spectrum

SJS is classified along a spectrum based on how much of the body's surface is affected. The classification matters medically and legally because more severe cases carry higher mortality rates and generate larger categories of long-term harm.

Stevens-Johnson Syndrome (SJS) is diagnosed when the skin detachment covers less than 10 percent of the body surface. Mortality for SJS alone is approximately 5 percent, but permanent eye damage, scarring, and chronic complications are common even in survivors of less severe cases.

SJS/TEN Overlap applies when 10 to 30 percent of the body surface is involved. This is the intermediate category, with a mortality rate of approximately 15 percent. The clinical picture at this stage closely resembles a severe burn injury.

Toxic Epidermal Necrolysis (TEN) is diagnosed when more than 30 percent of the body surface is affected. TEN has a mortality rate of up to 35 percent. Survivors frequently require months of hospitalization and years of ongoing care for eye, lung, skin, and psychiatric complications.

How It Begins

The early phase of SJS looks nothing like what it becomes. In the first one to three days, patients typically experience high fever, sore throat, burning or red eyes, and an overwhelming sense of illness. These symptoms are easy to mistake for the flu, a respiratory infection, or a common viral illness. That misidentification is one of the most dangerous things that can happen, because it delays stopping the drug that is causing the reaction.

As the disease progresses, a painful red or purplish rash appears, usually beginning on the trunk of the body. Blisters form first in or around the mouth, then spread across the face, eyes, and skin. The outer layer of skin begins to separate and shed. The process is similar in mechanism and appearance to a severe burn, and it requires the same intensity of medical care.

Mucous membrane involvement occurs in more than 90 percent of SJS cases. The mouth, eyes, esophagus, and genitals can all be affected. Eye complications, including corneal scarring and vision loss, are among the most devastating long-term consequences for survivors.

Why the Disease Progresses

One of the most legally significant facts about SJS is this: the reaction does not stop on its own while the causative drug is still in the body. Every day the triggering medication continues, the immune attack on the skin intensifies. Research published in the archives of dermatology found that early withdrawal of the causative drug reduced the risk of death by approximately 30 percent for each day the drug was stopped before blisters fully developed.

This is why failure to warn patients about early warning signs is not a minor oversight. It is the difference between a patient who stops the medication at the first rash and one who continues for three more days because no one told them what to watch for. Several of the drugs most strongly linked to SJS carry FDA black box warnings, the most serious safety designation the agency can require, specifically about this risk.

A Related Reaction: DRESS Syndrome

SJS is sometimes confused with a separate but similarly severe drug reaction called DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms). DRESS typically appears two to eight weeks after starting a drug, involves internal organ damage more prominently than skin detachment, and requires a different treatment approach. Misdiagnosing DRESS as SJS, or vice versa, can delay appropriate care and potentially support a malpractice claim in its own right. The FAQ section of this guide addresses DRESS in more detail.

The Scale of Drug-Induced Harm

Stevens-Johnson Syndrome is rare. That rarity is part of what makes it so dangerous: patients, families, and sometimes providers do not recognize it until it has already progressed. But rare does not mean uncommon enough to dismiss, and it does not mean unavoidable. The patients harmed by SJS each year are largely people who trusted a healthcare system that had both the knowledge and the responsibility to protect them. NORD's SJS patient resource offers a useful overview of incidence data and clinical context for families navigating a new diagnosis.

The patients most at risk are not random. Children on anticonvulsants for seizure disorders face elevated risk, particularly when doses are introduced too quickly. Older adults taking allopurinol for gout face risk that compounds with kidney function decline, which affects how the drug is cleared from the body. Patients of Han Chinese, Thai, and other Southeast Asian ancestry carry a genetic variant that dramatically increases the risk of SJS from carbamazepine, and an FDA-required screening test exists to identify this risk before the drug is ever prescribed. When these known risk factors are not accounted for, the harm is not bad luck. It is the result of a system that had the information and did not use it.

The true number of SJS and TEN cases is almost certainly higher than published incidence data reflects. Because early-stage SJS is frequently misdiagnosed as viral illness, allergic reaction, erythema multiforme, or another skin condition, a meaningful portion of cases may never be correctly classified. Patients who recover quickly, or whose cases are resolved without specialist involvement, may never know what actually happened to them.

Which Drugs Carry the Highest Risk

More than 200 medications have been associated with SJS and TEN in pharmacovigilance research. The drugs below represent those most consistently identified as high-risk across published epidemiological studies and FDA adverse event reporting. The chart shows relative SJS/TEN association strength, normalized so the highest-risk drug equals 100. These are proportional representations for comparison, not absolute case rates.

The presence of a drug on this list does not automatically mean the prescribing provider or manufacturer was negligent. What it does mean is that the risks were known, documented, and in many cases required to be disclosed under FDA labeling standards. The question in a legal case is whether the known risk was properly managed. If the standard of care required testing, titration, or patient counseling that did not happen, that gap is where a legal claim begins. Childers, Schlueter and Smith has written in depth about how allopurinol and Lamictal are frequently prescribed incorrectly and what that means for patients.

How Medical Negligence Causes SJS

SJS does not come out of nowhere. In most cases, it develops along a predictable path, and at multiple points along that path, a provider or manufacturer had an opportunity to prevent or limit the harm. When those opportunities are missed because of negligence rather than the unavoidable complexity of medicine, the people who were harmed have legal recourse.

The four most common categories of medical negligence in SJS cases are described below. More than one may apply in any given case, and a single case can involve multiple liable parties across multiple failure types.

Every patient prescribed a drug with a known SJS/TEN risk has the right to be told what early warning signs look like and what to do if they appear. That counseling is not optional. It is part of the standard of care for any provider who prescribes a high-risk drug, and it is required under FDA labeling standards for medications that carry SJS/TEN warnings, including mandatory patient Medication Guides for certain drugs.

Failure-to-warn claims arise when a patient was never told about the risk; when the risk was mentioned so briefly that no reasonable patient could act on it; or when the manufacturer failed to include, update, or adequately communicate the warning in prescribing information, patient-facing Medication Guides, or drug labeling. In cases where a drug carries a black box warning about SJS/TEN and the patient was not told about that warning, the failure is not subtle. It is documented, and it is legally actionable.

The failure to warn is also present on the pharmacy side. Pharmacists have an independent duty to counsel patients about serious drug risks. When a pharmacist dispenses a drug with a known SJS/TEN profile and says nothing about early warning signs, that silence can be part of a legal case alongside the prescribing physician's failure.

Some patients should not be prescribed certain drugs at all, and providers are expected to know this before writing a prescription. The clearest example involves the FDA's 2008 safety communication requiring prescribers to test for the HLA-B*1502 genetic variant before starting carbamazepine in patients of Han Chinese, Thai, Filipino, or other Southeast Asian ancestry. This genetic marker dramatically increases the risk of SJS from carbamazepine, and the FDA has required screening as the standard of care for over a decade.

When a provider prescribes carbamazepine to a patient of Southeast Asian descent without testing, and that patient develops SJS, the failure to test is not a minor procedural gap. It is a violation of a federally mandated standard of care.

Prescribing liability also arises from drug interactions. Several SJS-associated drugs are more dangerous in combination with other medications, and prescribers are expected to review a patient's full medication list. When a dangerous interaction was visible in the chart and the provider proceeded anyway, that is a prescription error with legal consequences.

Drugs like lamotrigine (Lamictal) and allopurinol have well-established titration protocols, meaning they must be started at a very low dose and increased slowly over weeks or months, under physician supervision. These protocols exist specifically because rapid dose escalation is one of the most consistent risk factors for SJS and TEN. They are not suggestions. They are part of the FDA-approved prescribing information for these drugs. Childers, Schlueter and Smith has documented numerous cases where these drugs were prescribed incorrectly, with the titration protocol ignored entirely.

When a provider starts a patient on too high a dose, escalates a dose too rapidly, or fails to schedule appropriate follow-up monitoring, any SJS that results is partly a product of that failure. For children in particular, weight-based dosing and conservative titration are especially critical, and deviations from pediatric prescribing guidelines are a frequent basis for claims.

Monitoring also includes follow-up appointments, blood level checks where applicable, and clear instructions about what symptoms should trigger an immediate call. A patient who was handed a prescription without any follow-up plan was not properly managed under the standard of care.

Early SJS is easy to mistake for something else. The prodromal flu-like symptoms lead providers toward viral diagnoses. The early skin changes are often called a drug rash, erythema multiforme, or an allergic reaction. These misdiagnoses are not just medically incorrect. They are dangerous, because they allow the causative drug to continue, and they delay the transfer to appropriate care.

Providers who see a febrile patient with skin changes and a recent new medication have a responsibility to consider SJS and act accordingly. That means stopping the suspect drug while the differential diagnosis is being worked out, not waiting for the rash to become undeniable. Delayed diagnosis of SJS is, in and of itself, a recognized basis for medical malpractice, and one that CSS has litigated successfully against both individual providers and hospital systems.

Who Can Be Held Accountable

One of the most important things to understand about SJS litigation is that responsibility rarely sits with one party. A single case can involve a physician who failed to warn, a pharmacist who failed to counsel, and a manufacturer whose labeling fell short of what the FDA requires. An experienced SJS attorney examines the entire chain of care to identify every party whose failure contributed to the harm. The CSS article on whether medical malpractice caused your SJS walks through each failure type in more detail.

Hospital and Facility Liability

When a patient presents to an emergency room or urgent care facility with fever, rash, and a recent new medication, the facility has a responsibility to consider SJS in the differential diagnosis. Emergency physicians, dermatology consultants, and hospitalists who misidentify early SJS as a benign drug rash or viral illness, and who send the patient home without stopping the drug or arranging follow-up, may expose the facility to malpractice liability in addition to the individual provider.

Facilities are also responsible for ensuring that patients who are diagnosed with SJS receive timely transfer to a burn center when their condition warrants it. A general hospital that attempts to manage a severe TEN case without the resources and expertise of a burn unit may be taking on unnecessary risk for the patient, and unnecessary legal risk for the institution.

What Compensation Covers

SJS and TEN are not injuries you recover from in a week. For most survivors, the damage extends across years, across organ systems, and across every dimension of a normal life. Understanding what compensation can cover means understanding what this condition actually costs, not just in medical bills, but in the things that are harder to put numbers on.

Acute Hospitalization

The initial hospitalization for SJS, and especially for TEN, is an intensive care event. Severe cases require treatment in a burn unit — the same environment used for third-degree burn victims — because the mechanism of injury is essentially identical: large-scale loss of the protective skin barrier. Burn unit care is among the most expensive categories of medical treatment in the American healthcare system. A 2023 study published in JAAD International found median acute hospitalization charges for SJS/TEN survivors around $55,000 — and that figure covers only the initial stay. Survivors then face months or years of reconstructive procedures, ophthalmologic care, pulmonary rehabilitation, and long-term specialist monitoring. Compensation covers the full arc of that treatment, not the negotiated rate your insurer accepted and not the amount left after co-pays and deductibles.

Reconstructive and Ongoing Wound Care

Skin that detaches from the body does not simply grow back to its original state. Many SJS survivors require specialized wound care, skin grafting, and reconstructive procedures over months to years after the acute phase. Mucous membrane involvement in the mouth, throat, and esophagus can require repeated dilation procedures if scarring causes stricture. Genital involvement can require reconstructive care and ongoing monitoring. These costs compound over time and belong in any complete accounting of damages.

Vision Care and Ophthalmology

Eye involvement is one of the most consequential long-term complications of SJS. Corneal scarring, chronic dry eye, symblepharon formation, and in severe cases partial or total vision loss, can require a lifetime of ophthalmological care, specialty contact lenses, surgical interventions, and, in some cases, support for permanent visual impairment. The American Academy of Ophthalmology recognizes SJS-related ocular disease as a distinct and serious category of injury requiring long-term specialist care. A damages calculation that does not account for the full trajectory of eye care is incomplete.

Pulmonary and Internal Organ Complications

The same mucosal destruction that affects the eyes and mouth can affect the lungs, esophagus, kidneys, and liver. Respiratory complications can require pulmonary rehabilitation and long-term specialist monitoring. Liver and kidney involvement during the acute phase can leave lasting organ damage. Sepsis, a life-threatening infection that occurs when bacteria from the damaged skin barrier enter the bloodstream, is one of the leading causes of death in SJS/TEN and can leave survivors with chronic health consequences even when it is survived. Recent research documented by CSS found that SJS survivors face a higher long-term risk of cardiovascular disease, including ischemic heart disease and cerebrovascular events, compared to the general population.

Permanent Scarring and Disfigurement

Permanent skin changes, discoloration, scarring, and textural damage are common in SJS survivors. These are not cosmetic concerns in the ordinary sense. They are visible, permanent reminders of a medical catastrophe, and they carry real psychological weight. Disfigurement damages exist precisely to compensate for the way this kind of physical change affects how a person moves through the world.

Psychological Harm

Surviving SJS or TEN is a traumatic experience. Patients spend weeks in acute agony, often sedated but still aware. They wake up looking fundamentally different from the person they were before. They live with the knowledge that a medication prescribed by a trusted doctor caused everything that happened to them. Post-traumatic stress disorder, depression, anxiety, and chronic pain conditions are well-documented in SJS survivors. The National Institute of Mental Health recognizes traumatic medical events as a recognized trigger for PTSD. Psychological harm and emotional distress are compensable damages, and they deserve to be taken as seriously as the medical bills.

Lost Income and Diminished Earning Capacity

A hospitalization lasting weeks or months, followed by months of recovery and ongoing specialist care, removes a person from the workforce. For survivors with permanent complications, particularly vision loss, chronic pain, or ongoing medical needs, the ability to return to prior employment may be permanently diminished. Lost wages and lost earning capacity are quantifiable and compensable. An economist can project these losses across the remainder of a working life.

Wrongful Death

When SJS or TEN takes a family member's life, compensation shifts to the family. Wrongful death damages can include the medical expenses incurred before death, funeral and burial costs, loss of the deceased person's financial contribution to the household, loss of companionship and parental guidance, and the grief and pain borne by the family. In cases involving reckless disregard for known risks, punitive damages may be available as well.

SJS in Specific Populations

While SJS can affect anyone, certain patients face substantially higher risk, and in many cases, that elevated risk is documented in the medical literature well enough that a provider who fails to account for it has a harder time arguing they met the standard of care. Three populations deserve particular attention: children, older adults, and patients with a specific genetic risk factor.

In children, medications are the most common cause of SJS and TEN, and anticonvulsants are the leading culprit. Children with epilepsy, mood disorders, or other neurological conditions are often prescribed drugs like lamotrigine (Lamictal), phenytoin, or carbamazepine. When those drugs are started too aggressively or escalated too quickly, the risk of SJS increases sharply.

The prescribing standards for children are not vague. Pediatric lamotrigine protocols, for example, specify starting doses measured in fractions of a milligram per kilogram of body weight, with increases permitted no more often than every two weeks. When a pediatric provider deviates from weight-based dosing guidelines, or when parents are not told to watch for fever, rash, or eye irritation in the days following a dose increase, any resulting SJS reflects a failure to follow the established standard.

Children cannot advocate for themselves the way adult patients can. They cannot read a drug label, call a nurse line, or independently assess whether their symptoms are serious. That places a greater burden on the prescriber and the pharmacist to communicate clearly with the parents, and it means that the absence of proper counseling in a pediatric SJS case is particularly difficult to defend.

Allopurinol, the most commonly implicated SJS drug in older adults, is prescribed to treat gout, a condition that disproportionately affects people over 65. In older patients, kidney function naturally declines with age. This matters because allopurinol is cleared from the body by the kidneys, and in a patient with reduced kidney function, the drug accumulates to levels that significantly increase SJS risk. Prescribing guidelines require dose adjustment based on creatinine clearance, a measure of kidney function.

When a provider prescribes standard-dose allopurinol to a patient with documented kidney impairment, without adjusting the dose and without monitoring kidney function over time, any resulting SJS is at least partly the product of a prescribing error. The risk was known, the guideline existed, and the provider had access to the patient's labs.

Older adults also frequently take multiple medications, which increases the risk of dangerous drug interactions. Polypharmacy, the simultaneous use of many drugs, is one of the most consistent themes in SJS cases involving elderly patients. Prescribers and pharmacists reviewing a complex medication list have both the tools and the obligation to identify combinations that raise the SJS risk profile.

In 2007, the FDA required drug manufacturers of carbamazepine to update labeling with a recommendation that providers test patients of Han Chinese or Thai descent for the HLA-B*1502 genetic allele before initiating treatment. The FDA's safety communication on this requirement is publicly available and makes clear that the screening obligation is part of the standard of care. The HLA-B*1502 variant is strongly associated with a dramatically elevated SJS/TEN risk in populations where it is prevalent, including Han Chinese, Thai, Filipino, Malaysian, and other Southeast Asian groups. The allele is also found in South Asian populations, though the association is less consistent.

The FDA's recommendation has since been extended to include other aromatic anticonvulsants, including oxcarbazepine and, in some guidelines, phenytoin and lamotrigine. The HLA-A*3101 allele has been associated with SJS risk from carbamazepine in Northern European populations as well.

A provider who prescribes carbamazepine to a patient with a Southeast Asian background without checking for HLA-B*1502 has failed to follow FDA-mandated prescribing guidance. If that patient develops SJS, the failure to test is direct evidence of deviation from the standard of care. Testing was available, it was required, and it was not done. That is a legally clear position.

Steps to Take After an SJS Diagnosis

If you or someone in your family has been diagnosed with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis, the immediate priority is medical. Everything legal follows from getting to the right facility and receiving the right care. But once the acute phase has stabilized, acting deliberately and early makes a real difference in your ability to pursue a legal claim.

Step 1: Stop the Suspected Drug

As soon as SJS or a severe drug reaction is suspected, stopping the causative drug is the most urgent medical intervention available. This step must happen under medical supervision, not at home, but it needs to happen quickly. Do not wait for confirmation of a specific diagnosis before addressing the medication. Every day the drug continues increases the severity of the reaction and the extent of potential harm. If your provider is hesitant to stop the drug or insists on continuing it despite your developing symptoms, that is a flag worth noting and discussing with an attorney later.

Step 2: Get to the Right Facility

Not all hospitals are equipped to manage SJS and TEN. Severe cases require a burn center, where staff are trained in the specific wound care, fluid management, and infection prevention protocols that these cases demand. The American Burn Association maintains a national directory of burn centers. If you or your family member was managed at a general hospital without transfer to a burn center and the outcome was worse as a result, that decision may be part of the legal case. CSS outlines what to do step by step in their guide to what to do if you have Stevens-Johnson Syndrome.

Step 3: Document Everything

Once the acute phase stabilizes, begin building a medical and prescription record. Request complete hospital records, including nursing notes, physician orders, lab results, and pathology reports. Obtain your pharmacy dispensing records, which will show every drug prescribed, the dose, and the date. Write down a timeline of when symptoms first appeared, which provider you saw and when, and what you were told at each stage. Memory fades; a written account created close to the event is far more useful than one reconstructed years later.

Step 4: Preserve Physical Evidence

Do not discard pill bottles, blister packs, or packaging from the drug associated with your reaction. The physical label, lot number, and package insert are potentially relevant to a product liability claim. Do not discard any written instructions you were given at the pharmacy or doctor's office. If you received a Medication Guide with the drug, keep it. If you were not given one and the drug required it under FDA rules, that absence is itself a documented failure. You can also submit an adverse event report through the FDA's MedWatch program, which creates a public record of your reaction and contributes to post-market drug safety monitoring.

Step 5: Speak With an SJS Attorney

SJS cases are not standard medical malpractice claims. They require attorneys who understand the pharmacology of high-risk drugs, the titration protocols that govern them, and the FDA labeling standards that define what manufacturers and prescribers owe their patients. Childers, Schlueter and Smith is one of the few firms in the United States with dedicated SJS and TEN litigation experience, including tried verdicts. Their guide to successfully pursuing an SJS lawsuit explains what to look for in an attorney and how these cases are built. Initial consultations are free and confidential, and the firm works on a contingency-fee basis, meaning you pay nothing unless the case results in a recovery. The statute of limitations clock begins running from the date of injury or diagnosis. There is no benefit to waiting.

Statutes of Limitations

The statute of limitations is the legal deadline for filing a lawsuit. In medical malpractice and product liability cases, missing that deadline generally means losing the right to sue, permanently, regardless of how strong the case was. Understanding how time limits work in SJS cases, and why they are more complicated than a simple calendar calculation, is essential for anyone considering legal action.

Georgia's Medical Malpractice Deadline

Georgia's medical malpractice statute of limitations, codified at OCGA Section 9-3-71, gives patients two years from the date the negligent act occurred, or from the date the patient knew or reasonably should have known about the injury and its connection to the negligent act. Georgia also has a five-year statute of repose, meaning that no medical malpractice claim can be filed more than five years after the alleged negligent act, regardless of when the patient discovered the connection. Because CSS handles SJS cases nationally, the specific deadline in your state may differ, and an attorney consultation is essential to determine the exact clock that applies to your circumstances.

The Discovery Rule and Why It Matters for SJS

SJS cases present a timing complication that many other malpractice cases do not. Patients who survive a hospitalization for a severe drug reaction are often told they had a "drug allergy," "toxic skin disorder," or "severe hypersensitivity reaction." They may not be told it was SJS. They may not be told that the drug was preventably dangerous or improperly prescribed. The connection between the drug, the prescribing failure, and the harm may not become apparent until months or years later, perhaps when reading about SJS for the first time, or when consulting a specialist who finally uses the correct terminology.

The discovery rule holds that the statute of limitations does not begin to run until the patient knew or reasonably should have known both that an injury occurred and that it may have been caused by the defendant's negligence. In SJS cases where the diagnosis itself was obscured or the drug connection was not made clear, this rule can meaningfully extend the filing window.

Product Liability Claims Against Manufacturers

In addition to a medical malpractice claim against the prescribing provider, patients may have a separate product liability claim against the drug manufacturer for inadequate labeling or failure to warn. Product liability claims typically run under different statutes of limitations than medical malpractice claims, and in some states, they allow a longer filing window. Having an attorney evaluate both theories simultaneously is the best way to ensure no viable path is missed.

If you are unsure whether your deadline has passed, speak with an attorney before drawing that conclusion yourself. Many patients assume their time has run when it has not, and some cases that appear time-barred under one theory remain viable under another. The analysis is fact-specific and requires legal expertise to do accurately. CSS's guide to pursuing an SJS lawsuit covers the legal process in more depth, including what to bring to an initial consultation.

Frequently Asked Questions

Related SJS Resources

This guide covers the broad legal framework for SJS and medical malpractice cases. The articles below go deeper on specific drugs, populations, legal theories, and the litigation process. The CSS cluster is one of the most comprehensive collections of SJS legal content published by any law firm in the United States.

SJS Legal Articles from Childers, Schlueter and Smith

Patient and Medical Resources

Get Legal Help

SJS and TEN cases are among the most complex and demanding in the medical malpractice field. They require attorneys who can speak the language of pharmacology and pharmacovigilance, who understand FDA labeling requirements and titration protocols, and who have actual trial experience with these specific injuries. That combination is rare.

Childers, Schlueter and Smith is one of the few firms in the United States with a documented track record of evaluating, litigating, and trying SJS and TEN cases to verdict. Based in Atlanta, the firm handles cases throughout Georgia and across the country. Since 2016, they have secured millions of dollars in total recoveries for SJS and TEN clients. Their reputation in this specific area brings referrals from other law firms that recognize the specialization required.